Literature DB >> 15848046

CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome.

Jacques-Eric Gottenberg1, Frédéric Lavie, Karim Abbed, Jacques Gasnault, Emilie Le Nevot, Jean-François Delfraissy, Yassine Taoufik, Xavier Mariette.   

Abstract

In animal models of autoimmunity, CD4 CD25high T cells play a key role in the control of the autoimmune process. Few studies have investigated the role of these cells in human autoimmune diseases. We aimed to investigate CD4 CD25high T cells in the peripheral blood of patients with primary Sjogren's syndrome (pSS). The proportion of blood CD4 CD25high T cells was determined by flow cytometry in 21 patients with pSS as determined by the American-European consensus group criteria and two groups of controls (18 patients with lumbar back pain of mechanical origin and 15 healthy blood donors). The suppressive function of CD4 CD25 cells was assessed using co-culture assays. The Vbeta repertoire of CD4 CD25 T cells was examined by flow cytometry. The proportion of CD4 CD25 T cells depended on age in patients and controls. In an age-matched comparison, no significant difference was observed in the proportion of total CD4 CD25low T cells between patients with pSS and controls (P=0.36). In contrast, the pool of CD4 CD25high was significantly increased in patients with pSS (8.5% vs 4.1% in controls, P=0.04). There was a slight but not significant higher proportion of CD4 CD25high cells in patients with a more active disease. CD4 CD25 T cells in patients with pSS effectively suppressed the proliferation of CD4 CD25- autologous responder T cells. The Vbeta repertoire of regulatory T cells from patients with pSS was polyclonal and was not significantly restricted as compared with that in controls. Functional CD4 CD25high regulatory cells are increased in patients with established pSS, through a reactive feedback, despite ongoing autoimmunity. These results suggest that pSS does not occur as a result of reduced level of CD4 CD25high regulatory T cells, nor as a defect of inhibition of proliferation of responder cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15848046     DOI: 10.1016/j.jaut.2005.01.015

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  45 in total

1.  Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.

Authors:  Anandharaman Veerapathran; Joseph Pidala; Francisca Beato; Xue-Zhong Yu; Claudio Anasetti
Journal:  Blood       Date:  2011-09-23       Impact factor: 22.113

2.  Lymphoma and other malignancies in primary Sjögren's syndrome.

Authors:  S R Pillemer
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

Review 3.  Immunosenescence of ageing.

Authors:  A L Gruver; L L Hudson; G D Sempowski
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996

4.  Novel animal models for Sjögren's syndrome: expression and transfer of salivary gland dysfunction from regulatory T cell-deficient mice.

Authors:  S-T Ju; W N Jarjour; R Sharma; L Zheng; X Guo; S M Fu
Journal:  J Autoimmun       Date:  2007-01-03       Impact factor: 7.094

Review 5.  T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology.

Authors:  Gikas E Katsifis; Niki M Moutsopoulos; Sharon M Wahl
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

6.  Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis.

Authors:  Gikas E Katsifis; Sofia Rekka; Niki M Moutsopoulos; Stanley Pillemer; Sharon M Wahl
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

Review 7.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

8.  Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors.

Authors:  Maria I Christodoulou; Efstathia K Kapsogeorgou; Niki M Moutsopoulos; Haralampos M Moutsopoulos
Journal:  Am J Pathol       Date:  2008-09-25       Impact factor: 4.307

9.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12

10.  Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development.

Authors:  Diana Milojevic; Khoa D Nguyen; Diane Wara; Elizabeth D Mellins
Journal:  Pediatr Rheumatol Online J       Date:  2008-12-01       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.